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Abstract 25 
Four indices of antimicrobial potency were determined for florfenicol and the pig pneumonia 26 
pathogens, Actinobacillus pleuropneumoniae and Pasteurella multocida. Minimum inhibitory 27 
concentration (MIC), minimum bactericidal concentration (MBC), mutant prevention 28 
concentration (MPC) and time-kill curves were determined in two matrices, broth and pig 29 
serum. Five overlapping sets of two-fold dilutions were used to increase accuracy of the 30 
measurements. MIC and MBC serum:broth ratios for A. pleuropneumoniae were 0.96:1 and 31 
1.07:1, respectively, and corresponding values for P. multocida were 0.72:1 and 0.50:1. The 32 
percentage binding of florfenicol to serum protein was 65.4%, and fraction unbound (fu) serum 33 
MICs were significantly lower, 2.71-fold and 3.82-fold, respectively, than predicted for free 34 
serum concentrations for A. pleuropneumoniae and P. multocida. Similar culture medium 35 
differences were obtained for MBC and MPC. MICs in serum and broth were increased 36 
significantly and progressively for high, medium and low initial inoculum counts. Serum 37 
MPC:MIC ratios for A. pleuropneumoniae and P. multocida were 12.5:1 and 13.6:1, 38 
respectively; ratios for broth were similar. The killing action of florfenicol had the 39 
characteristics of concentration dependency for both species in both growth media. These data 40 
indicate the value of using a biological medium, when determining microbiological potency 41 
indices, to predict dosage for clinical use. 42 
Keywords 43 
Minimum inhibitory concentration; Mutant prevention concentration; Florfenicol; 44 
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Introduction 49 
Florfenicol has been used in pigs for the therapy of pneumonia caused by the 50 
microorganisms Actinobacillus pleuropneumoniae, Pasteurella multocida and Bordetella 51 
haemolytica (Kehrenberg et al., 2008). In vitro studies have demonstrated bactericidal, 52 
concentration-dependent activity at concentrations close to the minimum inhibitory 53 
concentration (MIC) against some veterinary pathogens (Illambas et al., 2013; Sidhu et al., 54 
2014).   55 
 56 
Commonly used indices defining the potency of antimicrobial drugs are MIC, the 57 
lowest In vitro concentration inhibiting visible growth, and minimum bactericidal 58 
concentration (MBC), the lowest concentration producing a 3log10 reduction in bacterial count. 59 
Time-kill curves, quantifying the time course of growth inhibition, and as a separate measure 60 
mutant prevention concentration (MPC), are also used.  The latter is the lowest drug 61 
concentration preventing the growth of the least susceptible cells in high-density bacterial 62 
populations (Blondeau et al., 2004).  63 
 64 
The standardised methodologies for MIC determination are described in EUCAST 65 
(European Committee on Antimicrobial Susceptibility Testing) and CLSI (Clinical and 66 
Laboratory Standards Institute) guidelines [VET01-A3 (formerly M31-A3)]. These ensure 67 
standardisation and reproducibility between individual workers, laboratories and across both 68 
geographical regions and time (Papich, 2013).  However, for the objectives of the present study, 69 
these guidelines and standards have limitations. Regarding accuracy, MICs are determined 70 
using two-fold dilutions, giving a potential for up to 100% error on single isolate estimates.  71 
For many purposes, this is wholly acceptable, and indeed is necessary, when large numbers of 72 
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isolates are examined to establish MIC distributions. When plotted on a histogram, using a log-73 
base 2 distribution, the distributions are log-normal. These histograms facilitate the 74 
identification of wild-type distributions. The CLSI and EUCAST standards thereby enable 75 
determination of ECOFF and epidemiological breakpoints. 76 
 77 
Nevertheless, the lack of accuracy is a concern when MICs are to be correlated with 78 
pharmacokinetic data, as a basis for dose determination. Therefore, based on methods 79 
previously described (Aliabadi and Lees, 2001; Sidhu et al., 2010) five overlapping sets of two-80 
fold dilutions were used in this study to ensure accuracy within 20% of the true value for the 81 
small number of isolates studied, compared to the much larger numbers use to establish 82 
distributions. 83 
 84 
International guidelines and standards necessarily require the use of artificial broths, 85 
e.g. Cation Adjusted Mueller Hinton Broth (CAMHB) for MIC determinations.  Whilst each 86 
broth is formulated to optimize the growth of bacteria of a given species, they differ in 87 
composition, chemically and immunologically, to fluids encountered by pathogenic organisms 88 
in vivo. Hence, the quantitative determination of microbiological indices with improved 89 
accuracy and in biological fluid matrices, such as serum/plasma, can be regarded, for some 90 
drug classes and some microorganisms, as appropriate when applying 91 
pharmacokinetic/pharmacodynamic (PK/PD) integration and modelling methods to dose 92 
determination (Aliabadi et al.,  2002; Brentnall et al., 2013a; Lees et al., 2015). The terms MIC, 93 
MBC and MPC are therefore retained in this article to describe measurements in pig serum and 94 
broth. 95 
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 96 
The aims of this investigation were (1) to determine the non-protein bound fraction of 97 
florfenicol in pig serum; (2) for florfenicol against six pig isolates each of A. pleuropneumoniae  98 
and P. multocida (a) to determine MICs using five sets of overlapping two-fold dilutions, (b) 99 
to compare MICs, MBCs and MPCs for florfenicol in two matrices, CAMHB and pig serum, 100 
(c) to compare MICs using low, intermediate and high starting inoculum counts, (d) to establish 101 
time-kill curves for eight multiples of MIC in broth and serum; (3)  for two isolates each of P. 102 
multocida and A. pleuropneumoniae to determine the effect on  florfenicol MIC of (a) varying 103 
starting inoculum pH over the range 7.0 to 8.0 (b) varying broth concentrations of calcium and 104 
magnesium and (c) addition of serum to broth in varying proportions. CLSI and EUCAST do 105 
not set standards for MBC and MPC measurements. Therefore, methods used to determine 106 
MBC and MPC in both broth and serum and MIC in serum were non-standardised. 107 
 108 
  109 
Materials and methods 110 
Florfenicol serum protein binding  111 
A high pressure liquid chromatography (HPLC) method was used to analyse serum 112 
samples for florfenicol (de Craene et al., 1997). The system comprised a Beckman Ultrasphere 113 
ODS 5 µm 4.6 x 250 mm C18 column (Beckman Coulter), Dionex Ultimate 3000 pump and 114 
autosampler connected to a Dionex UVD340S detector (Thermo Fisher). UV detection was set 115 
to wavelength 224 nm for monitoring the signal, and at 200 and 400 nm for spectral 116 
information. Chromatographic data were analysed using Chromeleon Version 6.80 and 117 
concentrations of florfenicol were calculated using ratios of peak area, compared to internal 118 
standard. The standard curve concentrations were 0, 0.0025, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 5 119 
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and 10 µg/mL.  Standards in serum were run between samples with every assay to confirm 120 
linearity and reproducibility.  121 
 122 
Two sample sets were used: (1) spiked florfenicol standards in serum to determine the 123 
total concentration of protein bound and free drug; (2) an aliquot filtered using ultra-filtration 124 
devices (Amicon Ultra Centrifugal filters, Ultracel 10 k, Sigma-Aldrich) to determine the 125 
concentration in the protein-free fraction.  Each sample was analysed in triplicate. HPLC 126 
analysis and ultracentrifugation were conducted at ambient temperature.  127 
 128 
Selection of bacterial isolates 129 
Don Whitley Scientific supplied 20 isolates of P. multocida and three American Type 130 
Culture Collection (ATCC) reference strains to validate MIC tests; A. pleuropneumoniae 131 
ATCC 27090, Enterococcus faecalis ATCC 29212 and Escherichia coli ATCC 25922. These 132 
quality control organisms were incorporated in every MIC test; if the results did not match the 133 
ranges stated in CLSI guidelines, the experiment was repeated. Eight isolates of A. 134 
pleuropneumoniae were supplied by A. Rycroft (Royal Veterinary College). All P. multocida 135 
and A. pleuropneumoniae isolates were obtained from European Union (EU) field cases of pig 136 
pneumonia. They were stored at -80 oC in 10% Marvel® milk powder, 15% glycerol and sterile 137 
distilled water to 100%. The mixture was sterilized by boiling for 5 s, left to cool for 12 h and 138 
then boiled again for a further 5 s. 139 
 140 
Six isolates of each species were selected, based on three criteria: (1) logarithmic 141 
growth in artificial broth and pig serum; (2) sensitivity to florfenicol in disk diffusion assays 142 
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(data not shown); and (3) the highest and lowest broth MICs and four isolates with intermediate 143 
MICs determined using two-fold dilutions (data not shown). This pre-selection procedure 144 
ensured that all isolates could be used in subsequent studies and that they comprised a small 145 
but diverse range of susceptible isolates.  146 
 147 
Culture methods and bacterial counts 148 
For A. pleuropneumoniae Chocolate Mueller Hinton Agar (CMHA) was used to grow 149 
the organism on a solid medium and Columbia broth supplemented with 2 µg/mL nicotinamide 150 
adenine dinucleotide (NAD) was used as the liquid broth. Mueller Hinton Agar (MHA) 151 
supplemented with 5% defibrinated sheep blood was used to grow P. multocida and the liquid 152 
medium used was CAMHB.  They were incubated in a static incubator at 37 oC for 18-24 h.   153 
 154 
Bacterial counts were determined by serial dilution and spot plate counts. Ten-fold or 155 
100-fold dilutions were carried out in phosphate buffered saline. Three 10 µL drops of the 156 
appropriate dilutions were dropped onto the agar surface and allowed to dry. After 24 h 157 
incubation, the mean CFU count for each 10 µL was determined and multiplied by 100 and 158 
then multiplied by the dilution factor to give the original CFU/mL. 159 
 160 
Minimum inhibitory and minimum bactericidal concentrations 161 
MICs establish drug concentrations for inhibition of bacterial growth and MBCs 162 
determine the concentration to achieve bactericidal effects, defined as a 3log10 reduction in 163 
count. MICs and MBCs were determined in broth on 96 well plates by microdilution in 164 
accordance with CLSI guidelines for six isolates each of A. pleuropneumoniae and P. 165 
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multocida, except that: (1) five sets of overlapping two-fold serial dilutions of florfenicol were 166 
used and (2) determinations were also made in pig serum using five sets of overlapping two-167 
fold dilutions. The bacterial culture was grown to 0.5 McFarland Standard. This was diluted 168 
ten-fold to obtain the intended starting inoculum, 1-2 x 107 CFU/mL, which is higher than the 169 
CLSI recommendation of 5 x 105 CFU/mL. This higher inoculum count was selected to be 170 
equivalent clinically to a medium to heavy microbial challenge. 171 
 172 
Florfenicol solution, media and culture were added sequentially to the wells of 96-well 173 
plates. The plates were sealed and incubated statically at 37 oC for 24 h. Spot plate counts were 174 
prepared immediately after plate inoculation. Each test on each isolate was undertaken in 175 
triplicate. ATCC isolates were used in all assays at the CLSI recommended strength of 5 x 105 176 
CFU/mL. A positive control well contained medium and pathogen only and a negative control 177 
well contained medium and florfenicol only. Blank controls contained medium alone. MBCs 178 
were determined from the wells examined for growth to determine MIC and for five subsequent 179 
concentrations higher than MIC by spot plating.  180 
 181 
Mutant prevention concentration  182 
Fresh cultures were grown on agar and approximately 100 single CFUs collected on a 183 
sterile swab to inoculate culture from plates to a volumetric flask containing 200 mL of pre-184 
warmed broth.  This was placed in a static incubator overnight.  Next day, 1 mL of culture was 185 
added to 9 mL CAMHB and placed in an orbital incubator for 4 h at 37 oC and 180 rpm.  After 186 
4 h, the bacterial suspension yields a theoretical count of 1-2 x 1011 CFU/mL.  A spot plate was 187 
used to confirm inoculum density.   188 
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 189 
Drug concentrations used were 1, 2, 4, 8, 16, 32, 64 and 128 multiples of the MIC for 190 
each isolate.  The concentration ranges were narrowed down two further times. Florfenicol 191 
solution (0.5 mL volume) was applied to agar plates. After drying, 100 µL of culture were 192 
added and the plate allowed to dry.  Plates were incubated at 37 oC for 72 h and checked for 193 
growth every 24 h.  MPC was the lowest florfenicol concentration inhibiting bacterial growth 194 
completely after 72 h incubation. Each experiment was repeated in triplicate for six isolates of 195 
each test organism. The method was validated using a parallel design against that described by 196 
Blondeau (2009) and yielded similar results for two isolates of P. multocida repeated three 197 
times (results not shown).  198 
 199 
Inoculum size and MIC  200 
Three starting inoculum strengths were tested.  A 0.5 McFarland standard was made, 201 
providing a theoretical value of 1.5 x 108 CFU/mL (high).  Two 1:10 dilutions provided 1.5 x 202 
106 CFU/mL (medium) and two further 1:10 dilutions gave a count of 1.5 x 104 CFU/mL (low).  203 
MICs were determined in triplicate for six isolates each of P. multocida and A. 204 
pleuropneumoniae in CAMHB and serum.   205 
 206 
Antimicrobial growth (time-kill) curves 207 
Two to three colonies of the test isolate were added to 5 mL broth or serum and 208 
incubated overnight in an orbital incubator, as described above. Fifty µL of culture were diluted 209 
1:50 in pre-warmed broth/serum and incubated statically for 1 h at 37 oC to a 0.5 McFarland 210 
Standard. This was diluted ten-fold to obtain the intended starting inoculum, consistent with 211 
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MICs at 2 x 107 CFU/mL, and confirmed using colony counts.  Drug concentrations of 0.25, 212 
0.5, 1, 1.5, 2, 4, 6 and 8 x MIC were prepared in pre-warmed broth or serum.  Ten µL of culture 213 
were used to inoculate the dilutions to give a 1 mL final volume.  Fifty µL of each culture were 214 
sampled and bacterial count determined by serial dilution and spot plates at nine times: 0, 0.25, 215 
0.5, 0.75, 1, 2, 4, 8 and 24 h incubation.  A negative control contained no organism, whilst the 216 
positive control contained no drug.  Spot plates were examined for contamination and 217 
biochemical identification methods were applied.  Each test was repeated in triplicate for six 218 
isolates of both organisms in broth and serum. The lower limit of quantification (LLOQ) was 219 
33 CFU/mL. 220 
 221 
Data collection and analysis 222 
Data were recorded on Microsoft excel and processed using GraphPad Prism v6. The 223 
data were analysed using IBM SPSS Statistics 22 by Kruskal-wallis H with post-hoc Mann-224 
Whitney U test. 225 
 226 
Results 227 
Protein binding 228 
The mean (standard deviation (SD)) protein binding for florfenicol was 64.9 (17.38)% 229 
of total concentration for three batches of serum for concentrations over the range 0.1 to 10 230 
µg/mL. The degree of protein binding was independent of concentration. 231 
 232 
Minimum inhibitory, minimum bactericidal and mutant prevention concentrations 233 
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Table 1 indicates geometric means for MIC, MBC and MPC in broth and serum. All 234 
tests were conducted on six isolates of each species, and each test on each organism was carried 235 
out in triplicate. Then, for each triplicate analysis, means were determined. Table 1 shows the 236 
means of data for six isolates. For both organisms and all three indices of potency, there were 237 
no significant differences between broth and serum. However, for all three indices and both 238 
organisms, serum values corrected for protein binding (fu serum MIC) were significantly less 239 
than corresponding broth values. After MIC correction to allow for the microbiologically 240 
inactive protein bound fraction, the mean fu serum MIC was 0.11 µg/mL, which was 3.82-fold 241 
lower than the broth MIC. For the free drug concentration in serum, MBC was 5.75-fold lower 242 
than the MBC in broth. For A. pleuropneumoniae, MICs were similar in broth (0.38 µg/mL) 243 
and serum (0.39 µg/mL). However, again the fu serum MIC (0.14 µg/mL) was 2.71-fold lower 244 
than the broth MIC and the fu serum MBC was 2.79-fold lower than the broth MBC.   245 
  246 
These differences are clarified in Table 2, which indicates serum:broth ratios and 247 
fraction unbound (fu) serum:broth ratios. Differences for all three indices of potency, MIC, 248 
MBC and MPC, between broth and fu serum values were statistically significant.  Moreover, 249 
the amended ratios, fu serum:broth,  were broadly similar, 0.37:1, 0.33:1 and 0.45:1 for MIC, 250 
MBC and MPC, respectively, for A. pleuropneumoniae and corresponding values were 0.27:1, 251 
0.20:1 and 0.25:1 for P. multocida (Table 2). 252 
 253 
Table 3 presents the data as MBC:MIC and MPC:MIC ratios. The latter were similar 254 
for broth and serum, 10.3:1 and 12.5:1, respectively, for A. pleuropneumoniae, and 13.4:1 and 255 
13.6:1 for  P. multocida.   256 
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 257 
           Individual isolate MIC, MBC and MPCs for six isolates each of A. pleuropneumoniae 258 
and P. multocida in broth and serum are presented in Supplementary Figs. 1, 2 and 3. Further 259 
investigations of the effect of pH, cation adjustments and serum/broth mixtures on MIC were 260 
undertaken and are presented in Supplementary Figs. 4, 5, 6 and 7. 261 
 262 
Effect of inoculum size on MIC 263 
Tables 4 and 5 present mean (SD) MICs for inocula of three strengths, together with 264 
high:medium, high:low and medium:low MIC ratios for six isolates each of A. 265 
pleuropneumoniae and P. multocida. For P. multocida, high:low ratios were 5.3:1 (broth) and 266 
5.4:1 (serum) and  were statistically different (P < 0.01). High:medium MIC ratios were 2.6:1 267 
and 2.8:1 and were statistically different (P < 0.05) for broth and serum, respectively.  For A. 268 
pleuropneumoniae, high:low MIC ratios were 6.0:1 (broth) and 9.4:1 (serum) (broth ratio P < 269 
0.05, serum ratio P < 0.01), whilst high:medium ratios were  2.6:1 and 2.9:1 for broth and 270 
serum, respectively (P < 0.05 for both ).   271 
 272 
Time-kill curves 273 
Time-kill curves for florfenicol are illustrated in Figs. 1 (A. pleuropneumoniae) and 2 274 
(P. multocida), where 0, -3 and -4 log10 differences in CFU/mL are equivalent, respectively, to 275 
bacteriostatic, bactericidal and 10,000-fold reduction in count effects. For A. 276 
pleuropneumoniae, little inhibition occurred at concentrations less than 1 x MIC for both 277 
media. A bactericidal effect was achieved at 2 x MIC by 8 h in broth, and at 4 x MIC by 8 h in 278 
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serum. Virtual eradication (count less than 33 CFU/mL) was obtained after 24 h at 6 and 8 x 279 
MIC in both broth and serum.  280 
 281 
For P. multocida, both matrices by 4 h, 4 x MIC produced a bactericidal effect, 6 x MIC 282 
demonstrated greater than 4 log10 decrease in count and for 4-8 x MIC there was virtual 283 
eradication in broth  at 24 h. For serum, virtual eradication was achieved at 24 h with 6 and 8 284 
X MIC.  There was no re-growth at 24 h.  The action of florfenicol in both fluids for both 285 
species was classed as concentration-dependent.  286 
 287 
Discussion 288 
Some authors recommend restriction of the term MIC to measurements made in broths 289 
prescribed in CLSI and EUCAST guidelines. However, MIC is a widely accepted and 290 
understood term, even when growth matrices other than those required to meet CLSI and 291 
EUCAST standards have been used. For example, MIC was used by Honeyman et al. (2015) 292 
to compare potencies of several tetracyclines in broth and a 50% broth:50% serum mixture. 293 
The differences obtained could not be accounted for solely by the degree of drug-protein 294 
binding. Furthermore, Zeitlinger et al. (2011) has commented that “bacteria with appropriate 295 
and well-defined growth in the selected medium should be employed….in order to be able to 296 
extrapolate data  from various models to in vivo situations, models should always attempt to 297 
mimic physiological conditions as closely as possible”. These considerations relate to accuracy 298 
of MIC determination; this can generally be obtained from broth MIC results by applying a 299 
robust scaling factor to bridge in vitro MHB to in vivo relevant serum/plasma/blood values. 300 
 301 
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             For porcine pneumonia, it would be theoretically desirable to monitor drug potency by 302 
measuring MIC in pulmonary epithelial ling fluid (PELF). However, collection of cell-free 303 
PELF in sufficient volumes for MIC determinations on a reasonable number of isolates would 304 
be challenging. Therefore, if one determines serum MIC values and corrects them for protein 305 
bound (inactive) drug fraction, this might be preferable to use of virtually protein-free broths 306 
for dose prediction purposes, for some drug classes, such as macrolides/triamilides, as shown 307 
for tulathromycin (Toutain et al., 2016). This is because, at steady state equilibrium, the free 308 
serum concentration will be the same as the free biophase concentration. Moreover, drug 309 
activity in serum is much closer to activity in broth from a biological fluid composition 310 
perspective. Thus, serum (but not broths) is likely to have concentrations of electrolytes, urea, 311 
leucocytes, glucose etc. closer to the biophase than do broths (Zeitlinger et al., 2011). Hence, 312 
whilst serum is not identical to the biophase matrix, it is likely to be closer to the biophase in 313 
chemical composition than broths, and indeed in respect of some immunological components 314 
also. Brentnall et al. (2012) reported on the differing chemical compositions of Mueller Hinton 315 
Broth and calf serum.  Of course, the in vitro data presented in this paper should be now be 316 
used in dose estimation studies, based on PK/PD modelling, and these doses, in turn, will 317 
require confirmation (or not) in disease model studies and clinical trials.     318 
The mean percentage protein binding of florfenicol in pig serum, over the therapeutic 319 
concentration range of 0.1 to 10 µg/mL, was 64.9%. This is higher than the binding reported 320 
for other species; 17.8% for calf serum (Illambas et al., 2013) 26.6% in the goat (Atef et al., 321 
2001) and 18.1-21.1% in Muscovy ducks (El-Banna, 1998). These differences impact on dose 322 
schedules for clinical use.  323 
 324 
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If the only potency difference between broth and serum for antimicrobial drugs is 325 
attributable to protein binding in the latter fluid and the virtual absence of protein (notably 326 
albumin) in most broths, the correction for binding would yield serum:broth ratios of 1:1 for 327 
each index. In this study, the fu serum:broth MIC, MBC and MPC ratios were 2.71:1, 3.82:1 328 
and 3.10:1 (A. pleuropneumoniae) and 5.75:1, 2.27:1 and 3.99:1 (P. multocida) respectively. 329 
These ratios reflect the correction, which is routinely made to allow for the fact that protein 330 
bound drugs are microbiologically inactive (Merrikin et al., 1983; Zeitlinger et al., 2004). 331 
These experimental values were significantly different from the predicted 1:1 ratio. Therefore, 332 
the potency in serum exceeded that in broth and the former may be a more relevant index for 333 
linking with pharmacokinetic data to predict dose schedules for clinical use. Indeed, the present 334 
findings indicate that use of serum MIC data would generate estimated doses some three to 335 
four times lower than those predicted by broth MICs and, if calculated doses were based on 336 
MBCs, they would be 3 to 6 times lower.  337 
 338 
These serum/broth differences emphasise the importance not only of comparing 339 
potency in several matrices (e.g. differing broths, serum/plasma, inflammatory exudate) but 340 
also of  acquiring larger data sets in these fluids. Nevertheless, this study with a small number 341 
of isolates for each bacterial species quantified inter-isolate variability in the antimicrobial 342 
action of florfenicol against two bacterial pathogens, A. pleuropneumoniae and P. multocida, 343 
for four indices of activity in two matrices, broth and serum. These findings on serum/broth 344 
differences should be extended also to other pathogenic species, as potency is a factor 345 
determining dose and differences are likely to be matrix, drug, species and strain dependent. In 346 
future studies, it will be important to determine if sera from different breeds/environmental 347 
conditions/continents/countries/disease states/ages etc. will lead to differing results in potency, 348 
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as monitored by indices such as MIC, MBC and MPC. Therefore, it will be necessary to ensure 349 
standardisation across laboratories. This paper is no more than a first step in this direction.    350 
 351 
To achieve clinical and bacteriological efficacy, as well as minimising the emergence 352 
of resistance, an important consideration is pathogen load. For prophylaxis, metaphylaxis and 353 
treatment early in the course of disease, the bacterial pathogen load may be small or absent. 354 
Many drugs will then prevent or cure disease at low dose rates, in association with natural body 355 
defences. The major challenge, however, is to achieve a bacteriological cure, when pathogen 356 
density in the biophase is high. In this study, pathogen load affected significantly MICs in both 357 
broth and serum and for both species investigated. However, it should be noted that florfenicol 358 
is not licensed for prophylactic use. 359 
 360 
De Jong et al. (2014) documented florfenicol MIC distribution frequencies for A. 361 
pleuropneumoniae and P. multocida for EU pig isolates between 2002 and 2006.  The MICs 362 
for P. multocida isolates were 0.25 µg/mL (72/230), 0.5 µg/mL (155/230) and 1 µg/mL (2/230). 363 
The data, valid for the objectives set, were obtained using CLSI methodologies and therefore 364 
did not use five overlapping sets of two-fold dilutions, nor take account of serum/broth 365 
differences. Nevertheless, their broth MIC values are of a similar order of magnitude to those 366 
reported in this study.  367 
 368 
The mean broth MPCs in this study were 3.84 and 5.63 µg/mL for A. pleuropneumoniae 369 
and P. multocida, respectively.  These are comparable with may be compared data for 285 370 
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cattle isolates of M.haemolytica: the MPC90 was 8 µg/mL and the MIC50 was 4 µg/mL 371 
(Blondeau et al., 2012). 372 
 373 
Pharmacokinetic data for florfenicol in pigs administered intramuscularly at 10 mg/kg, 374 
using licensed products, can be linked with the serum potency data generated in this study  (Liu 375 
et a., 2003). The maximum in vivo serum concentration (free plus bound) was 3.2 µg/mL, 376 
whilst mean serum MICs and MPCs were 0.39, 4.89 µg/mL (A. pleuropneumoniae), 0.30, and 377 
4.08 µg/mL (P. multocida). The comparison indicates that the currently recommended 378 
florfenicol dose provides concentrations above MICs for at least 48 h but MPC was not 379 
attained, even at the maximum in vivo concentration. Therefore, a dose to ensure avoidance of 380 
resistance emergence may not be quite attainable. 381 
 382 
For A. pleuropneumoniae and P. multocida the range of eight multiples of MIC, 0.25 383 
to 8 x MIC, was sufficient to establish bacteriostatic, bactericidal and virtual eradication effects 384 
at 24 h and to plot the time course of killing pattern at earlier times. This was rapid for multiples 385 
of 4 x MIC and greater for both A. pleuropneumoniae and P. multocida. The killing action was 386 
classified as concentration dependent.   387 
 388 
For future studies, refinements of the methodology used in this investigation would be 389 
to establish time-kill curves not only in serum but also in the presence of other "natural" 390 
constituents, such as antibodies and leucocytes. The present time-kill studies were based on the 391 
widely accepted exposure of the bacteria to fixed florfenicol concentrations for a fixed time 392 
period. In vivo, concentrations in both serum and the biophase first increase and then decrease 393 
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after systemic, non-vascular dosing.  Therefore, In vitro time-kill techniques, such as hollow 394 
fibre models of growth inhibition, which better reflect the circumstances of clinical exposure, 395 
could be used in future studies to simulate in vivo concentration-time profiles. 396 
 397 
Nightingale and Murakawa (2002) noted a greater potency of some macrolides in serum 398 
compared to broth and they recommended use of the former fluid to generate data relevant to 399 
clinical in vivo circumstances.  Mitchell et al. (2012, 2013) reported markedly greater potency 400 
of the triamilides, tulathromycin and gamithromycin, in in vitro MIC and time-kill studies for 401 
the calf pathogen Mycoplasma mycoides mycoides small colony. Likewise, Godinho et al. 402 
(2005) and Godinho (2008) reported 8-fold reductions in MIC for both M. haemolytica and P. 403 
multocida of calf origin, when broth was supplemented with 40% calf serum, compared to 404 
100% broth MICs. In extension of this work, comparing 100% serum with 100% broth, Toutain 405 
et al. (2016) reported MIC broth:serum MIC ratios of 47:1 and 53:1, respectively, for these two 406 
pathogens. Differences were far greater than could be accounted for by correction of serum 407 
MICs for protein binding, and indicated potentiation of the action of tulathromycin by some 408 
serum factor. In stark contrast, Brentnall et al. (2012, 2013b) obtained much higher MICs in 409 
serum compared to broth for oxytetracycline and, even with correction for protein binding, the 410 
difference was 6-fold. These and the present data indicate drug specific properties interacting 411 
with growth matrix; one possibility if differing rates of logarithmic growth of bacteria in broths 412 
and serum, potentially leading to different levels of challenge.   Additionally, for some drug 413 
classes e.g. tetracyclines, several actions have been reported that may influence clinical 414 
outcome, including immunomodulaory and anti-inflammatory properties (Pasquale & Tan, 2005; 415 
Woo et al., 1999). 416 
 417 
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Conclusions 418 
Matrix dependent effects on quantitative MIC, MBC and MPC values were obtained 419 
for florfenicol; after correction for binding to serum protein, all three indices of potency were 420 
significantly lower in serum than in broth, indicating that correction for protein binding (whilst 421 
necessary) is not sufficient to account for matrix potency differences. Time-kill data 422 
demonstrated a co- or concentration-dependent killing action in both growth matrices. It is the 423 
hypothesis of this paper that in vitro plasma/serum concentration of florfenicol is more likely 424 
to be close to the in vivo concentration required for efficacy than potency estimated in broth. 425 
Differences between broth and porcine serum may have implications for optimization of 426 
dosage schedules for clinical use. 427 
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Table 1 544 
A. pleuropneumoniae (APP) and P. multocida (PM) MIC, MBC and MPC for broth, serum and 545 
unbound fraction serum concentrations (fu serum)a. 546 
Organism Medium MIC MBC MPC 
APP 
Broth 0.38 (0.11)  2.79 (0.54)  3.84 (0.70)  
Serum 0.39 (0.17)  2.61 (0.83) 4.89 (1.93) 
 fu Serum 0.14 (0.06)* 0.92 (0.29)* 1.71* 
 
PM 
Broth 0.42 (0.13)  1.38 (1.23)  5.63 (1.70)  
Serum 0.30 (0.16)  0.69 (0.67) * 4.08 (1.69)  
 fu Serum 0.11 (0.06)* 0.24 (0.08)* 1.43* 
aGeometric means (SD) of florfenicol concentrations: triplicate analyses for each of six isolates 547 
of each organism (n=6). Significance of differences between broth and fu serum: *P <0.01. 548 
MIC = minimum inhibitory concentration, MBC = minimum bactericidal concentration, MPC 549 
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Table 2 564 
A. pleuropneumoniae (APP) and P. multocida (PM) serum:broth and unbound fraction serum 565 
concentration (fu serum):broth ratiosa for MIC, MBC and MPC  566 
Organism Medium MIC MBC MPC 
APP 
Serum:broth  0.96:1 1.07:1 1.27:1 
fu Serum:broth  0.37:1 0.33:1 0.45:1 
 
PM 
Serum:broth  0.72:1 0.50:1 0.73:1 
fu Serum:broth  0.27:1 0.20:1 0.25:1 
aRatios for triplicate analyses for each of six isolates of each organism (n=6). MIC = minimum 567 
inhibitory concentration, MBC = minimum bactericidal concentration, MPC = mutant 568 
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Table 3 585 
A. pleuropneumoniae (APP) and P. multocida (PM) MBC:MIC and MPC:MIC ratiosa for broth 586 
and serum 587 
Organism Medium MBC:MIC MPC:MIC 
APP 
Broth 7.36 : 1 10.32 : 1 
Serum 6.64 : 1 12.47 : 1 
PM 
Broth 3.26 : 1 13.41 : 1 
Serum 2.26 : 1 13.60 : 1 
aTriplicate analyses for each of six isolates of each organism (n=6). MIC = minimum inhibitory 588 

















   26 
Table 4 606 
P. multocida (PM) MICs for broth and serum with three inoculum sizesa, serum:broth ratios 607 
and inoculum size ratios  608 
Inoculum size Broth MIC Serum MIC Serum:broth ratio 
High 0.78 (0.19) 0.73 (0.16) 0.94 : 1 
Medium 0.30 (0.10) 0.26 (0.02) 0.86 : 1 
Low 0.15 (0.04) 0.13 (0.04) 0.92 : 1 
    
High:medium ratio 2.6 : 11 2.8 : 13  
High:low ratio  5.3 : 12  5.5 : 14  
Medium:low ratio          2.1 : 1 1.9 : 1  
aInoculum size: high (108 CFU/mL), medium (106 CFU/mL) and low (104 CFU/mL). Minimum 609 
inhibitory concentration (MIC) values are geometric means (SD) for triplicate analyses for 6 610 
isolates (n=6). Differences in MIC ratios between inoculum sizes: P = 10.03, 20.01, 30.03, 40.01. 611 
  612 
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Table 5 613 
A. pleuropneumoniae (APP) MICs for broth and serum with three inoculum sizesa, serum:broth 614 
ratios and inoculum size ratios 615 
Inoculum size Broth MIC Serum MIC Serum:broth ratio 
High 0.81 (0.22) 1.30 (0.55) 1.62 : 1 
Medium 0.32 (0.10) 0.44 (0.04) 1.40 : 1 
Low 0.13 (0.02) 0.14 (0.01) 1.05 : 1 
    
High:medium ratio 2.6 : 11 2.9 : 13  
High:low ratio 6.0 : 12 9.4 : 14  
Medium:low ratio 2.4 : 1 3.2 : 1  
aInoculum size: high (108 CFU/mL), medium (106 CFU/mL) and low (104 CFU/mL). Minimum 616 
inhibitory concentration (MIC) values are geometric means (SD) for triplicate analyses for six 617 
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Figure 1. In vitro inhibition of growth of A. pleuropneumoniae over 24 h exposure to 8 632 
multiples of MIC in (A) Columbia broth supplemented with NAD and (B) pig serum (n = 6). 633 
Bars indicate standard deviation. LLOQ= 33 CFU/mL. 634 
 635 
 636 
  637 
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Figure 2. In vitro inhibition of growth of P. multocida over 24 h exposure to 8 multiples of 638 
MIC in (A) CAMHB and (B) pig serum (n = 6). Bars indicate standard deviation. LLOQ = 33 639 
CFU/mL. 640 
 641 
